Renaissance Technologies's BMRN Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 1.89 M shares of BioMarin Pharmaceutical Inc. (BMRN) worth $102.56 M, representing 0.14% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 48 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in BMRN, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 911,000 shares. Largest reduction occurred in Q2 2024, reducing 425,871 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's BioMarin Pharmaceutical (BMRN) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioMarin Pharmaceutical (BMRN) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2013 | +280,071 | New Buy | 280,071 | $70.35 |
| Q1 2014 | -280,071 | Sold Out | 280,071 | $0.00 |
| Q2 2015 | +123,671 | New Buy | 123,671 | $136.78 |
| Q3 2015 | +138,900 | Add 112.31% | 262,571 | $105.32 |
| Q4 2015 | -69,000 | Reduce 26.28% | 193,571 | $104.76 |
| Q1 2016 | -61,500 | Reduce 31.77% | 132,071 | $82.48 |
| Q2 2016 | -132,071 | Sold Out | 132,071 | $0.00 |
| Q4 2016 | +39,371 | New Buy | 39,371 | $82.83 |
| Q1 2017 | -39,371 | Sold Out | 39,371 | $0.00 |
| Q2 2017 | +126,871 | New Buy | 126,871 | $90.82 |
| Q3 2017 | +193,400 | Add 152.44% | 320,271 | $93.07 |
| Q4 2017 | -58,900 | Reduce 18.39% | 261,371 | $89.17 |
| Q1 2018 | -132,800 | Reduce 50.81% | 128,571 | $81.07 |
| Q2 2018 | -100,100 | Reduce 77.86% | 28,471 | $94.20 |
| Q3 2018 | +178,500 | Add 626.95% | 206,971 | $96.97 |
| Q4 2018 | -163,400 | Reduce 78.95% | 43,571 | $85.15 |
| Q1 2019 | +278,400 | Add 638.96% | 321,971 | $88.83 |
| Q2 2019 | +215,400 | Add 66.90% | 537,371 | $85.65 |
| Q3 2019 | +18,700 | Add 3.48% | 556,071 | $67.40 |
| Q4 2019 | -353,600 | Reduce 63.59% | 202,471 | $84.55 |
| Q1 2020 | -183,371 | Reduce 90.57% | 19,100 | $84.50 |
| Q2 2020 | -19,100 | Sold Out | 19,100 | $0.00 |
| Q1 2021 | +365,571 | New Buy | 365,571 | $75.51 |
| Q2 2021 | -75,600 | Reduce 20.68% | 289,971 | $83.44 |
| Q3 2021 | +91,500 | Add 31.55% | 381,471 | $77.29 |
| Q4 2021 | +269,589 | Add 70.67% | 651,060 | $88.35 |
| Q1 2022 | -159,889 | Reduce 24.56% | 491,171 | $77.10 |
| Q2 2022 | +243,592 | Add 49.59% | 734,763 | $82.87 |
| Q3 2022 | +9,708 | Add 1.32% | 744,471 | $84.77 |
| Q4 2022 | -114,200 | Reduce 15.34% | 630,271 | $0.10 |
| Q1 2023 | +150,800 | Add 23.93% | 781,071 | $0.10 |
| Q2 2023 | -48,433 | Reduce 6.20% | 732,638 | $0.09 |
| Q3 2023 | -150,867 | Reduce 20.59% | 581,771 | $88.48 |
| Q4 2023 | -195,100 | Reduce 33.54% | 386,671 | $96.42 |
| Q1 2024 | +155,400 | Add 40.19% | 542,071 | $87.34 |
| Q2 2024 | -425,871 | Reduce 78.56% | 116,200 | $82.33 |
| Q3 2024 | +302,671 | Add 260.47% | 418,871 | $70.29 |
| Q4 2024 | +17,000 | Add 4.06% | 435,871 | $65.73 |
| Q1 2025 | +459,900 | Add 105.51% | 895,771 | $70.69 |
| Q2 2025 | +911,000 | Add 101.70% | 1.81 M | $54.97 |
| Q3 2025 | +86,800 | Add 4.80% | 1.89 M | $54.16 |
Renaissance Technologies's BioMarin Pharmaceutical Investment FAQs
Renaissance Technologies first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q4 2013, acquiring 280,071 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held BioMarin Pharmaceutical Inc. (BMRN) for 48 quarters since Q4 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q2 2025, adding 1,806,771 shares worth $99.32 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 1,893,571 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $102.56 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 0.14% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 1,893,571 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.